

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/634,979	08/05/2003	Hartmut Strobel	DEAV2002/0056 US NP	8786	
5487 75	90 01/18/2006		EXAMINER		
ROSS J. OEH		POWERS, FIONA			
AVENTIS PHA ROUTE 202-20	RMACEUTICALS INC.	ART UNIT	PAPER NUMBER		
MAIL CODE: I	=	1626			
BRIDGEWATI	ER, NJ 08807		DATE MAILED: 01/18/2006	5	

Please find below and/or attached an Office communication concerning this application or proceeding.

								
Office Action Summary		Application No.	Applicant(s)	Applicant(s)				
		10/634,979	STROBEL ET AL					
		Examiner	Art Unit					
			Fiona T. Powers	1626				
Period fo	 The MAILING DATE of this community 	nication app	ears on the cover sheet w	vith the correspondence a	ddress			
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD IN CHEVER IS LONGER, FROM THE IN INSIGN SO IT IN IT I	MAILING DA s of 37 CFR 1.13 munication. statutory period w y will, by statute,	TE OF THIS COMMUN 6(a). In no event, however, may a ill apply and will expire SIX (6) MO cause the application to become A	ICATION. reply be timely filed NTHS from the mailing date of this BANDONED (35 U.S.C. § 133).				
Status								
1) 🛛	Responsive to communication(s) fil	ed on 26 Oc	tober 2005.					
	This action is FINAL . 2b)⊠ This action is non-final.							
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims			·				
4)🖂	Claim(s) <u>1-10</u> is/are pending in the	application.		·				
•	4a) Of the above claim(s) <u>2,4,5,9 and 10</u> is/are withdrawn from consideration.							
5)	5) Claim(s) is/are allowed.							
6)🛛	5)⊠ Claim(s) <u>1,3 and 6-8</u> is/are rejected.							
7)	Claim(s) is/are objected to.							
8)	Claim(s) are subject to restri	ction and/or	election requirement.					
Applicati	on Papers							
9)	The specification is objected to by the	ne Examiner						
· · · · · · · · · · · · · · · · · · ·				by the Examiner.				
	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority ι	ınder 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:								
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the priority documents have been received in this National Stage							
	application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.								
Attachmen	' '							
	e of References Cited (PTO-892)		. 4) Interview	Summary (PTO-413)				
	e of Draftsperson's Patent Drawing Review (I nation Disclosure Statement(s) (PTO-1449 o			s)/Mail Date Informal Patent Application (PT	O-152)			
	r No(s)/Mail Date <u>9/29/03, 11/2/05</u> .		6) Other:					

Application/Control Number: 10/634,979

Art Unit: 1626

Receipt is acknowledged of the information disclosure statements filed September 29, 2003 and November 2, 2005, which have been entered in the file.

Applicant's election with traverse of Group II, Claims 1, 6, 7 and 8 where X is S and claim 3 in the reply filed on October 26, 2005 is acknowledged. The traversal is on the ground(s) that the claimed compounds have a substantial structural feature and share a common utility. This is not found persuasive because the heterocyclic ring bound to the amide group can vary since X can be NR³⁰, S, O, CH=CH, N=CH or CH=N.

The requirement is still deemed proper and is therefore made FINAL.

Claims 2, 4, 5, 9 and 10 stand withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on October 26, 2005.

Claim 3 is objected to because of the following informalities: claim 3 does not end in a period. Appropriate correction is required.

Art Unit: 1626

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 3, 6, 7 and 8 are rejected under 35 U.S.C. 102(b) as being anticipated by Ritchey (US 4560549), cited or Alanine et al. (WO 01/97786), cited by applicants.

The references disclose the claimed compounds and pharmaceutical compositions where X is S and R⁵ is phenyl or heteroaryl. Note Compound (b) of the abstract of Ritchey and Examples1-25, 27-38, 41-45, 48-51, 53-63 and 66-75 of Alanine et al.

Claims 1, 3, 6 and 7 are rejected under 35 U.S.C. 102(b) as being anticipated by Kume et al. (US 4675331) or Ueno et al. (US 6020470) or Petrie et al. (US 6342514) or British Patent 1,345,552 or British Patent 1,596,383, cited.

The references disclose the claimed compounds where X is S and R⁵ is phenyl, naphthyl or heteroaryl. Note Examples 1 to 3 and Compound Nos. 3-5, 15-27 and 29-33 of Table 1 and Comparative compound A in column 9 of Kume et al.; Example 14 in column 19 of Ueno et al.; the benzothiazole compounds of Drawing

Application/Control Number: 10/634,979

Art Unit: 1626

Sheet Nos. 23,, 24, 33, 47-49, 53-57 and 72 of Petrie et al.;

Example Nos. 3, 7-12, 16, 17, 22 and 23 of Tables I-III of

British Patent 1,345,552; and Compound Nos. 4, 10, 18 and 21 of

British Patent 1,596,383.

Claims 1, 3, 7 and 8 are rejected under 35 U.S.C. 102(b) as being anticipated by Henzi (US 2399026) or Abe et al. (US 4929623), cited.

The references disclose the claimed compounds and pharmaceutical compositions where X is S and R⁵ is phenyl, naphthyl or heteroaryl. Note Examples 1 to 4 of Henzi; and Example 5 in column 27 and Compound Nos. 51, 54, 55 and 56 of Table 5 in columns 39-40 of Abe et al.

The references made of record and not relied upon show the state of the art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Fiona T. Powers whose telephone number is 571-272-0702. The examiner can normally be reached on Monday - Friday 8:00 AM to 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/634,979 Page 5

Art Unit: 1626

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Fiona T. Powers
Fiona T. Powers
Primary Examiner
Art Unit 1626

ftp January 11, 2006